Home LiteratureArticle Details
PMID: 18621920 Published · ppublish English Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.

Journal of lipid research ·Vol. 49 ·No. 11 ·2008-11-00 ·Pages 2302-11

Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM

Abstract

4F is an anti-inflammatory, apolipoprotein A-I (apoA-I)-mimetic peptide that is active in vivo at nanomolar concentrations in the presence of a large molar excess of apoA-I. Physiologic concentrations ( approximately 35 microM) of human apoA-I did not inhibit the production of LDL-induced monocyte chemotactic activity by human aortic endothelial cell cultures, but adding nanomolar concentrations of 4F in the presence of approximately 35 microM apoA-I significantly reduced this inflammatory response. We analyzed lipid binding by surface plasmon resonance. The anti-inflammatory 4F peptide bound oxidized lipids with much higher affinity than did apoA-I. Initially, we examined the binding of PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine) and observed that its oxidized products bound 4F with an affinity that was approximately 4-6 orders of magnitude higher than that of apoA-I. This high binding affinity was confirmed in studies with defined lipids and phospholipids. 3F-2 and 3F(14) are also amphipathic alpha-helical octadecapeptides, but 3F-2 inhibits atherosclerosis in mice and 3F(14) does not. Like 4F, 3F-2 also bound oxidized phospholipids with very high affinity, whereas 3F(14) resembled apoA-I. The extraordinary ability of 4F to bind pro-inflammatory oxidized lipids probably accounts for its remarkable anti-inflammatory properties.

MeSH Terms
Amino Acid Sequence Anti-Inflammatory Agents, Non-Steroidal/metabolism Apolipoprotein A-I/metabolism,physiology Cells, Cultured Humans Inflammation Mediators/metabolism,physiology Lipid Peroxidation/physiology Molecular Mimicry/physiology Molecular Sequence Data Peptides/metabolism Phospholipids/metabolism Protein Binding/physiology
Chemicals
APOA1 protein, human Anti-Inflammatory Agents, Non-Steroidal Apolipoprotein A-I D-4F peptide Inflammation Mediators L-4F peptide Peptides Phospholipids
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Van Lenten Brian J
Department of Medicine David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1679, USA. [email protected]
Wagner Alan C
Jung Chun-Ling
Ruchala Piotr
Waring Alan J
Lehrer Robert I
Watson Andrew D
Hama Susan
Navab Mohamad
Anantharamaiah G M
Fogelman Alan M
References (40)
40 references, click to expand
  1. ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers.
    J Biol Chem. 2007 Jan 19;282(3):1980-8 PMID: 17114186
  2. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes.
    Circulation. 2005 Jun 14;111(23):3126-34 PMID: 15939814
  3. Protein targets of oxidized phospholipids in endothelial cells.
    J Lipid Res. 2008 Mar;49(3):510-20 PMID: 18071189
  4. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.
    J Lipid Res. 2000 Sep;41(9):1495-508 PMID: 10974057
  5. Two homologous apolipoprotein AI mimetic peptides. Relationship between membrane interactions and biological activity.
    J Biol Chem. 2004 Dec 3;279(49):51404-14 PMID: 15358763
  6. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice.
    Circulation. 2004 Sep 21;110(12):1701-5 PMID: 15353488
  7. Inhibition of lipopolysaccharide-induced inflammatory responses by an apolipoprotein AI mimetic peptide.
    Circ Res. 2005 Aug 5;97(3):236-43 PMID: 16002747
  8. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
    Circ Res. 2005 Nov 25;97(11):1190-7 PMID: 16224061
  9. An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol.
    Biochemistry. 2004 May 4;43(17):5073-83 PMID: 15109266
  10. Cytoprotective gene HO-1 and chronic rejection in heart transplantation.
    Transplant Proc. 2006 Dec;38(10):3259-62 PMID: 17175242
  11. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice.
    Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1426-32 PMID: 15845909
  12. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet.
    J Lipid Res. 2008 Jan;49(1):192-205 PMID: 17925450
  13. Role of endothelial nitric oxide synthase in the regulation of SREBP activation by oxidized phospholipids.
    Circ Res. 2006 Mar 31;98(6):768-76 PMID: 16497987
  14. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.
    J Lipid Res. 2001 Apr;42(4):545-52 PMID: 11290826
  15. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions.
    J Biol Chem. 2002 Oct 11;277(41):38517-23 PMID: 12145296
  16. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Circulation. 2004 Jun 29;109(25):3215-20 PMID: 15197147
  17. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein.
    J Biol Chem. 1999 Aug 27;274(35):24787-98 PMID: 10455151
  18. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo.
    J Biol Chem. 1997 May 23;272(21):13597-607 PMID: 9153208
  19. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet.
    J Lipid Res. 2006 Oct;47(10):2148-60 PMID: 16835442
  20. Apolipoprotein A-I mimetic peptides.
    Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1325-31 PMID: 15831812
  21. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
    J Lipid Res. 2007 Sep;48(9):1915-23 PMID: 17570869
  22. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice.
    J Lipid Res. 2002 Mar;43(3):477-85 PMID: 11893784
  23. Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats.
    J Pharmacol Exp Ther. 2007 Aug;322(2):514-20 PMID: 17488882
  24. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells.
    Circulation. 2003 Mar 25;107(11):1520-4 PMID: 12654610
  25. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice.
    Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1432-41 PMID: 17496220
  26. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.
    Circulation. 2002 Jan 22;105(3):290-2 PMID: 11804981
  27. Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1.
    J Lipid Res. 2006 Jan;47(1):107-14 PMID: 16210729
  28. Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity.
    J Biol Chem. 2004 Jun 18;279(25):26509-17 PMID: 15075321
  29. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.
    J Lipid Res. 2008 Jun;49(6):1344-52 PMID: 18323573
  30. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.
    Int J Pept Protein Res. 1990 Mar;35(3):161-214 PMID: 2191922
  31. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta.
    J Biol Chem. 2002 Mar 1;277(9):7271-81 PMID: 11751881
  32. Role for sterol regulatory element-binding protein in activation of endothelial cells by phospholipid oxidation products.
    Circ Res. 2004 Oct 15;95(8):780-8 PMID: 15388640
  33. Inflammation/oxidation in chronic rejection: apolipoprotein a-i mimetic peptide reduces chronic rejection of transplanted hearts.
    Transplantation. 2007 Jul 27;84(2):238-43 PMID: 17667816
  34. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease.
    Circulation. 2003 May 13;107(18):2337-41 PMID: 12732610
  35. High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinflammatory to anti-inflammatory.
    Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1346-53 PMID: 17379837
  36. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
    J Lipid Res. 2008 Jun;49(6):1268-83 PMID: 18323574
  37. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits.
    J Lipid Res. 2007 Nov;48(11):2344-53 PMID: 17693626
  38. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes.
    Circulation. 2004 Nov 16;110(20):3252-8 PMID: 15533864
  39. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.
    J Lipid Res. 2001 Jul;42(7):1096-104 PMID: 11441137
  40. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide.
    Circulation. 2002 Aug 27;106(9):1127-32 PMID: 12196340
Article Info
Journal
Journal of lipid research
Abbr.
J Lipid Res
ISSN
0022-2275
Published
2008-11-00
Epub
2008-00-11
Pages
2302-11
Language
English
Region
United States
NLM ID
0376606
PMCID
PMC2563211
Subset
IM
Grants
NHLBI NIH HHS · P01 HL030568 · United States
NHLBI NIH HHS · P01 HL034343 · United States
NHLBI NIH HHS · HL-30568 · United States
NHLBI NIH HHS · HL-34343 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]